X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Biosimilar uptake is increasing and so are health savings

By Jocelyn Ulrich  |    October 17, 2022
There has been a lot of talk recently about the biosimilars marketplace and what role biosimilars play in reducing health care costs. We’re here to set the record straight about how these medicines...   Read More

CMS coverage policies restrict patient access to important treatment options for Alzheimer’s disease

By Gabby Migliara  |    September 1, 2022
There’s been a lot of discussion this year about the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) for new Alzheimer’s treatments finalized earlier this year in...   Read More

The Senate’s latest price setting proposal will undermine: Patient access to medicines

By Nicole Longo  |    July 26, 2022
Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting...   Read More

New research shows competition driven by biosimilars helps control costs in Part B

By Gabby Migliara  |    July 19, 2022
Discussions about spending in Medicare Part B, including a recent report from the Medicare Payment Advisory Commission, or MedPAC, too often overlook how competition between medicines drives down the...   Read More

CMS coverage decision restricts access to treatments for Alzheimer’s disease

By Nicole Longo  |    June 22, 2022
This year’s Alzheimer’s and Brain Awareness Month offers an important opportunity to remember the severe toll that Alzheimer’s takes on patients and family caregivers. Unfortunately, this year also...   Read More

Part B 101: Three charts show the program helps control costs for health care system and enrollees

By Nicole Longo  |    February 18, 2022
Medicare Part B covers a wide range of health care services, including physician office visits, hospital outpatient care and medical equipment. It also covers medicines that are usually administered...   Read More

PhRMA submits comments urging CMS to withdraw coverage proposal

By Lauren Neves  |    February 11, 2022
In comments submitted this week, PhRMA urged the Centers for Medicare & Medicaid Services (CMS) to withdraw its proposed national coverage determination (NCD) for monoclonal antibodies (mAbs) for the...   Read More

It’s a new year, but sadly Congress is still pursuing flawed price setting policies

By Nicole Longo  |    January 25, 2022
As we kick off 2022, Congress has a number of priorities they are aiming to tackle, including the Build Back Better Act (BBBA). Unfortunately, the bill includes policies that would take the...   Read More

Post-approval research save lives. Why is Congress trying disincentivize it?

By Andrew Powaleny  |    December 17, 2021
While some in Congress continue to claim the latest drug pricing plan in Washington is “negotiation,” that is far from the truth. The reality is that the current plan gives the government a new...   Read More

A price control by any other name would still put patients at risk and threaten innovation

By Nicole Longo  |    December 9, 2021
Some policymakers in DC are laser focused on giving the government the power to “negotiate” in Medicare. What they aren’t saying is that this isn’t negotiation at all. They essentially just want the...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."